Showing results (561-570 of 709) with videos related to

Sort By:
Pageof 71
Frontiers in Oncology|June 28, 2021
Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?Lukas Müller, Felix Hahn, Aline Mähringer-Kunz, et al.
British Journal of Cancer|July 5, 2006
Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4C C Schimanski, R Bahre, I Gockel, et al.
European Journal of Biochemistry|June 10, 2000
Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cellsS H Hoischen, P Vollmer, P März, et al.
Hamostaseologie|July 30, 2021
COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case ReportMarie-Kristin Schwaegermann, Lukas Hobohm, Johanna Rausch, et al.
Clinical and Translational Gastroenterology|July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular CarcinomaR K Kelley, E Gane, E Assenat, et al.
Liver Cancer|May 17, 2024
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular CarcinomaGhassan K Abou-Alfa, Peter R Galle, Yee Chao, et al.
BMC Cancer|February 14, 2016
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentDaniel Grimm, Jonas Lieb, Veronika Weyer, et al.
Journal of Clinical Gastroenterology|September 19, 2013
Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC RegistryArndt Weinmann, Sandra Koch, Ina M Niederle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Activity and Safety of Avelumab in High-Grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive after Chemotherapy (AveNEC Trial)Christian Fottner, Leonidas Apostolidis, Sebastian Krug, et al.
Liver Cancer|August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 StudyMasatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Pageof 71